AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25187919 — intervention group
Group type: COMPARATOR
Intervention: NTx
Number of subjects: 700
Study 25187919 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT
Number of subjects: 700
Study 25190134 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin
Number of subjects: 116
Study 25190134 — intervention group
Group type: EXPERIMENTAL
Intervention: Presepsin (4th quartile levels)
Number of subjects: 116
Study 25190203 — intervention group
Group type: EXPERIMENTAL
Intervention: Globus pallidus infarcts in patients with isolated methylmalonic acidemia
Number of subjects: 40
Study 25190203 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroanatomic scoring system based on infarct patterns
Number of subjects: 40
Study 25190203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of globus pallidus infarcts by methylmalonic acidemia class
Number of subjects: 40
Study 25190203 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunar infarcts in the pars reticulata of the substantia nigra
Number of subjects: 40
Study 25190591 — intervention group
Group type: COMPARATOR
Intervention: Higher ESS (≥1 Pa)
Number of subjects: 21
Study 25190591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ESS (<1 Pa)
Number of subjects: 21
Study 25190605 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal therapy (RCT)
Number of subjects: 708
Study 25190633 — intervention group
Group type: EXPERIMENTAL
Intervention: PROVIVO instrument (Patient-Reported Outcomes of long-term survivors after allogeneic SCT)
Number of subjects: 15
Study 25190633 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CTCAE item bundle
Number of subjects: 15
Study 25190651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive optics scanning light ophthalmoscopy (AOSLO)
Number of subjects: 75
Study 25190651 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 75
Study 25190651 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence (AF)
Number of subjects: 75
Study 25190651 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning light ophthalmoscopy (SLO)
Number of subjects: 75
Study 25190651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AOSLO and OCT
Number of subjects: 75
Study 25190675 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥5.9% (41 mmol/mol)
Number of subjects: 16122
Study 25190675 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 5.9-6.4% (41-46 mmol/mol)
Number of subjects: 16122
Study 25191915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine (0.2-1.6 mg/d, mean dose 0.4 mg/d, mean maximum dose 0.7 mg/d)
Number of subjects: 15
Study 25191915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose buprenorphine
Number of subjects: 15
Study 25191939 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-inh) administered intravenously at a dose 30-fold greater than that approved for hereditary angioedema (HAE).
Number of subjects: 0
Study 25191939 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-inh) at a dose of 2000 units in humans.
Number of subjects: 0
Study 25191939 — intervention group
Group type: EXPERIMENTAL
Intervention: C1-esterase inhibitor (C1-inh) combined with polysulfated macromolecules (heparin and dextran sulfate).
Number of subjects: 0
Study 25192373 — intervention group
Group type: EXPERIMENTAL
Intervention: AOSpine Knowledge Forum Tumor model for data collection
Number of subjects: 1495
Study 25192373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective data collection
Number of subjects: 1495
Study 25192373 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective data review
Number of subjects: 1495
Study 25192414 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab treatment
Number of subjects: 0
Study 25192745 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.
Number of subjects: 106
Study 25193617 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release mesalamine tablets formulated with MMX technology, 8 weeks of treatment for active mild-to-moderate UC.
Number of subjects: 343
Study 25193617 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release mesalamine tablets formulated with MMX technology, 12 months of maintenance treatment for quiescent UC.
Number of subjects: 343
Study 25193672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 2227
Study 25193933 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25195991 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening using computed tomography angiography (CTA)
Number of subjects: 48
Study 25195991 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD-specific counseling
Number of subjects: 48
Study 25195991 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (CTA)
Number of subjects: 48
Study 25195991 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and post-screening questionnaires
Number of subjects: 48
Study 25196123 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein-1 (MCP-1)
Number of subjects: 581
Study 25196123 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage inflammatory protein-1α (MIP-1α)
Number of subjects: 581
Study 25196123 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated upon activation normal T cell expressed and secreted (RANTES)
Number of subjects: 581
Study 25196123 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES
Number of subjects: 581
Study 25196783 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 60
Study 25197009 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (once daily)
Number of subjects: 86
Study 25198021 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSwNP
Number of subjects: 45
Study 25198021 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSsNP
Number of subjects: 45
Study 25198021 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 25198193 — intervention group
Group type: COMPARATOR
Intervention: Icatibant administered by healthcare professionals (HCPs) in FAST-3
Number of subjects: 145
Study 25198193 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant administered by healthcare professionals (HCPs) in IOS
Number of subjects: 145
Study 25198193 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (combined HCP and self-administration) in IOS
Number of subjects: 145
Study 25198661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar (15 mg/day) combined with gemcitabine (1,000 mg/m(2) on days 1 and 8) and cisplatin (80 mg/m(2) on day 1) for a maximum of four cycles.
Number of subjects: 30
Study 25199919 — intervention group
Group type: EXPERIMENTAL
Intervention: Striatal dopamine D2-like receptor binding potential (D2BP) measured using positron emission tomography with [(18)F]fallypride
Number of subjects: 43
Study 25199997 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg single dose
Number of subjects: 32
Study 25200052 — intervention group
Group type: COMPARATOR
Intervention: HeartWare Ventricular Assist Device only
Number of subjects: 382
Study 25200052 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent valve procedures
Number of subjects: 382
Study 25200052 — intervention group
Group type: EXPERIMENTAL
Intervention: No tricuspid valve procedure (TVP)
Number of subjects: 382
Study 25200052 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplant tricuspid regurgitation severity
Number of subjects: 382
Study 25200052 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 382
Study 25200593 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative experience as described by patients and caregivers through daily diary entries assessing functional autonomy, postoperative pain, and caregiver burden.
Number of subjects: 105
Study 25200593 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diary responses from patients and caregivers regarding their postoperative experience.
Number of subjects: 105
Study 25200610 — intervention group
Group type: EXPERIMENTAL
Intervention: (64)Cu-MM-302
Number of subjects: 0
Study 25201017 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak isometric muscle force measurements for lower extremity (LE) muscle groups
Number of subjects: 42
Study 25201017 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual walking
Number of subjects: 42
Study 25201017 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast walking
Number of subjects: 42
Study 25201017 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaled LE peak muscle forces
Number of subjects: 42
Study 25201017 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaker subjects
Number of subjects: 42
Study 25201017 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak isometric force of the knee flexors and ankle plantar flexors
Number of subjects: 42
Study 25201125 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraSeal polyethylene glycol (PEG) gel used as a spacer during low-dose rate brachytherapy.
Number of subjects: 0
Study 25201318 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 8 weeks
Number of subjects: 58
Study 25201318 — intervention group
Group type: COMPARATOR
Intervention: COMT Met-carriers
Number of subjects: 58
Study 25201318 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional anisotropy measure
Number of subjects: 58
Study 25201624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult Myopathy Assessment Tool (AMAT)
Number of subjects: 114
Study 25201624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMAT items
Number of subjects: 114
Study 25201624 — intervention group
Group type: EXPERIMENTAL
Intervention: AMAT total scores
Number of subjects: 114
Study 25202139 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly bortezomib 1.6 mg/m²
Number of subjects: 70
Study 25202139 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly bortezomib 1.3 mg/m²
Number of subjects: 70
Study 25203178 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-susceptible Staphylococcus aureus (MSSA) SSTI
Number of subjects: 1203
Study 25203178 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin-resistant Staphylococcus aureus (MRSA) SSTI
Number of subjects: 1203
Study 25203178 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA SSTI
Number of subjects: 1203
Study 25203178 — intervention group
Group type: EXPERIMENTAL
Intervention: MSSA SSTI
Number of subjects: 1203
Study 25203178 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall S. aureus colonization
Number of subjects: 1203
Study 25203178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-field gel electrophoresis (PFGE) analysis
Number of subjects: 1203
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan test (cut-off 0.5)
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan test (cut-off 1.0)
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactomannan test (cut-off 3.0)
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: β-D-glucan test (cut-off 80 pg/ml)
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: β-D-glucan test (cut-off 200 pg/ml)
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral-flow device tests
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycological culture
Number of subjects: 221
Study 25203869 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable/proven invasive pulmonary aspergillosis
Number of subjects: 221
Study 25204423 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient educational materials (PEMs) from Women & Infants Hospital
Number of subjects: 0
Study 25204423 — intervention group
Group type: COMPARATOR
Intervention: Patient educational materials (PEMs) from four laboratories in the US and one in Europe
Number of subjects: 0
Study 25204541 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 159
Study 25204541 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain severity
Number of subjects: 159
Study 25204854 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk of obstructive sleep apnea (OSA) assessed by the Berlin Questionnaire.
Number of subjects: 302
Study 25204854 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased risk of cardiometabolic disease (CMR) assessed by biomarkers including Lipid Accumulation Product (LAP) and Triglyceride-Glucose Index (TyG Index).
Number of subjects: 302
Study 25204977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 0
Study 25204977 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 25204977 — intervention group
Group type: EXPERIMENTAL
Intervention: Former intensive group
Number of subjects: 0
Study 25204977 — intervention group
Group type: COMPARATOR
Intervention: Former conventional treatment group
Number of subjects: 0
Study 25205777 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial assessments (Mental Health Assessment and Dynamic Referral for Oncology)
Number of subjects: 836
Study 25205777 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of mental health counseling, total number of cancer-related symptoms, and race/ethnicity
Number of subjects: 836
Study 25205858 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis with monopolar return, anodic-first polarity, short pulse widths (100 μs), long interphase gaps (500 μs), and high stimulation rates (≥400 pps)
Number of subjects: 3
Study 25205858 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis
Number of subjects: 3
Study 25207162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-magnitude whole-body vibration
Number of subjects: 34
Study 25207162 — intervention group
Group type: COMPARATOR
Intervention: Low-magnitude whole-body vibration
Number of subjects: 34
Study 25207813 — intervention group
Group type: EXPERIMENTAL
Intervention: More recess physical activity (PA)
Number of subjects: 186
Study 25207813 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of total PA
Number of subjects: 186
Study 25207813 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active school transportation
Number of subjects: 186
Study 25207813 — intervention group
Group type: EXPERIMENTAL
Intervention: More time spent in sedentary behavior (SB)
Number of subjects: 186
Study 25207813 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PA
Number of subjects: 186
Study 25208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment approaches for abdominal pain in IBD patients; specific interventions not detailed.
Number of subjects: 0
Study 25208108 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the source(s) of pain in patients with IBD; specific interventions not detailed.
Number of subjects: 0
Study 25208608 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 488
Study 25209003 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-omic molecular profiling (MMP) informed selection of approved cancer treatments
Number of subjects: 28
Study 25209376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin combined with bevacizumab (four cycles, final cycle without bevacizumab)
Number of subjects: 46
Study 25209376 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant capecitabine and oxaliplatin combined with bevacizumab
Number of subjects: 46
Study 25209396 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical sphingomyelin liposomes (4 weekly instillations)
Number of subjects: 14
Study 25209657 — intervention group
Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (VCE)
Number of subjects: 200
Study 25210104 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) administered for 30 days, median dose 5.65 mg/kg/day twice daily
Number of subjects: 12
Study 25210104 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (BNZ) administered for 30 days
Number of subjects: 12
Study 25210883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 3 ng/mL
Number of subjects: 108
Study 25210883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 4-hour glucagon stimulation test (GST) with a peak GH cutoff of 1 ng/mL
Number of subjects: 108
Study 25210883 — intervention group
Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 108
Study 25211055 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 15990
Study 25211055 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 15990
Study 25211344 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/Ad
Number of subjects: 15
Study 25211344 — intervention group
Group type: COMPARATOR
Intervention: AdCA
Number of subjects: 15
Study 25211526 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography alone
Number of subjects: 100
Study 25211526 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography with mediastinoscopy
Number of subjects: 100
Study 25211526 — intervention group
Group type: COMPARATOR
Intervention: Endosonography
Number of subjects: 100
Study 25211526 — intervention group
Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 100
Study 25212533 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVAal (3.1 ± 1.1 cmH2O/μV)
Number of subjects: 10
Study 25212533 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVAhigh
Number of subjects: 10
Study 25212533 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVAlow
Number of subjects: 10
Study 25212533 — intervention group
Group type: COMPARATOR
Intervention: PSVal (17 ± 2 cmH20)
Number of subjects: 10
Study 25212533 — intervention group
Group type: COMPARATOR
Intervention: PSVhigh
Number of subjects: 10
Study 25212533 — intervention group
Group type: COMPARATOR
Intervention: PSVlow
Number of subjects: 10
Study 25213088 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy
Number of subjects: 31
Study 25213088 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 31
Study 25213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat maintenance therapy (oral agent) for 21 consecutive days starting day + 60 after autologous transplant, followed by a week off for up to 11 cycles.
Number of subjects: 23
Study 25213183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat maintenance therapy
Number of subjects: 23
Study 25213604 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise strategy
Number of subjects: 0
Study 25213604 — intervention group
Group type: COMPARATOR
Intervention: Control exercise group
Number of subjects: 0
Study 25213741 — intervention group
Group type: EXPERIMENTAL
Intervention: Women veterans
Number of subjects: 24965
Study 25213741 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American female veterans
Number of subjects: 24965
Study 25213741 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American veterans with diabetes
Number of subjects: 24965
Study 25214022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy with live birth deliveries
Number of subjects: 12
Study 25214022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy with transient worsening of renal function
Number of subjects: 12
Study 25214022 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated pregnancy
Number of subjects: 12
Study 25214022 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncomplicated pregnancy after previous pregnancy
Number of subjects: 12
Study 25214517 — intervention group
Group type: EXPERIMENTAL
Intervention: W28 arm (24 weeks of BOC/PEGIFN/RBV after 4 weeks of PEGIFN/RBV lead-in)
Number of subjects: 21
Study 25214517 — intervention group
Group type: EXPERIMENTAL
Intervention: W48 arm (44 weeks of BOC/PEGIFN/RBV after 4 weeks of PEGIFN/RBV lead-in)
Number of subjects: 21
Study 25214517 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR12TND rate
Number of subjects: 21
Study 25214517 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events
Number of subjects: 21
Study 25214544 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage CRC patients
Number of subjects: 291
Study 25214544 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with early-stage CRC
Number of subjects: 291
Study 25214838 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of the A allele of the FTO rs9939609 gene
Number of subjects: 1119
Study 25214838 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1119
Study 25214838 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor metabolic control
Number of subjects: 1119
Study 25216871 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 68
Study 25217112 — intervention group
Group type: EXPERIMENTAL
Intervention: BIL >1 mg/dl (>17.1 µmol/l) and CHE ≤ 5,900 U/l
Number of subjects: 336
Study 25217112 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 336
Study 25217112 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-days mortality
Number of subjects: 336
Study 25217112 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD, APRI, and CPT scores
Number of subjects: 336
Study 25217217 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 25217392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib + Rituximab
Number of subjects: 5
Study 25217734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels (Group 1a, ≤5 ng/mL)
Number of subjects: 81
Study 25217734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D levels (Group 1b, 5-15 ng/mL)
Number of subjects: 81
Study 25217734 — intervention group
Group type: COMPARATOR
Intervention: Normal 25(OH)D levels (Group 2, >15 ng/mL)
Number of subjects: 81
Study 25217734 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Group 1a and Group 1b
Number of subjects: 81
Study 25217734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher 25(OH)D levels
Number of subjects: 81